Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
You may also be interested in...
The first clinical trial results for Roche’s brain shuttle technology in Alzheimer’s patients showed that trontinemab cleared more amyloid and at a faster pace than its failed predecessor gantenerumab.
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.